Wednesday, July 26, 2017

Enter Title

Minimize
*|MC:SUBJECT|*
OPSUMIT (MACITENTAN) receives PBAC Recommendation.
 
Email not displaying correctly?
View it in your browser.
View at phsanz.com.au

PBAC RECOMMENDATION

OPSUMIT (MACITENTAN) RECEIVES PBAC RECOMMENDATION FOR PULMONARY ARTERIAL HYPERTENSION (PAH)
       Indication: Pulmonary Arterial Hypertension (PAH)
  • The PBAC recommended the listing of macitentan, on the basis that it should be available only under special arrangements under section 100.
  • The Section 100 Highly Specialised Drugs (HSD) Program Authority Required listing should be for the treatment of
    • idiopathic pulmonary arterial hypertension (PAH)
    • PAH associated with connective tissue disease
    • PAH associated with congenital heart disease,
    • in patients with World Health Organisation Functional Classification III and IV who meet certain criteria

For more information please refer to the Actelion Website.

*|FACEBOOK:LIKE|**|MC:TOPSHARE|*  Forward to Friend 
Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.
*|IFNOT:ARCHIVE_PAGE|* *|LIST:DESCRIPTION|*

Our mailing address is:
*|HTML:LIST_ADDRESS_HTML|* *|END:IF|*
 
unsubscribe from this list   update subscription preferences 
Copyright 2011 by PHSANZ